Ulcerative Colitis
‘Promise of lasting efficacy’: Guselkumab outperforms placebo, ustekinumab in Crohn’s
WASHINGTON — In patients with active Crohn’s disease, guselkumab was superior to both placebo and standard-of-care ustekinumab after 48 weeks of treatment, according to late-breaking data from the phase 3 GALAXI program.
Evolocumab shows particular CV benefit in those with autoimmune disease, inflammation
Patients with atherosclerosis and elevated LDL plus autoimmune or inflammatory disease may derive particular CV benefit from PCSK9 inhibition with evolocumab, a speaker reported.
Entyvio effective in pediatric IBD, ‘should be included in our treatment paradigm’
WASHINGTON — Entyvio is “safe and effective” for maintaining sustained steroid-free remission at 1 year in children with inflammatory bowel disease, more so in those with ulcerative colitis vs. Crohn’s disease, according to a researcher.
TRIUMPH: 58% of acute severe UC patients responded ‘within 2 days’ of starting Xeljanz
WASHINGTON — Nearly 60% of patients with acute severe ulcerative colitis responded to Xeljanz 10 mg twice daily by day 7, with one-third of patients in steroid-free remission by 6 months, according to interim analysis data presented here.
Simlandi launches in U.S. as third interchangeable Humira biosimilar
Simlandi injection, an interchangeable biosimilar to Humira, is now available in the U.S. for the treatment of psoriatic arthritis, plaque psoriasis and other conditions, Teva Pharmaceuticals and Alvotech announced in a press release.
Statin use linked to ‘sharp 86% risk reduction’ for primary sclerosing cholangitis in IBD
WASHINGTON — Statin use was associated with up to a 90% risk reduction for new-onset primary sclerosing cholangitis among patients with inflammatory bowel disease, according to data presented at Digestive Disease Week.
‘Promising’ low-calorie, plant-based diet may improve inflammation, therapy response in UC
WASHINGTON — “Even at short intervals,” an intermittent low-calorie, plant-based diet may improve inflammation and response to medical therapy among patients with moderately to severely active ulcerative colitis, according to a presenter.
Q&A: ‘Future is bright’ for use of microbiota therapeutics in patients with IBD
In a Healio exclusive, Ari Grinspan, MD, predicted that while microbiota therapeutics are currently “not ready for prime time,” they will eventually become part of the treatment strategy for patients with inflammatory bowel disease.
FDA warns of ‘rare risk’ for thiopurine-related intrahepatic cholestasis of pregnancy
The FDA has issued a safety alert warning patients and health care providers of a “rare risk of intrahepatic cholestasis of pregnancy” linked to thiopurine use.
FDA approves high-concentration, citrate-free form of interchangeable biosimilar Cyltezo
The FDA has approved a citrate-free, high-concentration formulation of the interchangeable adalimumab biosimilar Cyltezo to treat multiple chronic inflammatory diseases, according to the manufacturer.